Competitive enzyme immunoassay for diagnosis of human brucellosis

Autores
Lucero, Nidia E.; Foglia, Luis; Ayala, Sandra M.; Gall, David; Nielsen, Klaus
Año de publicación
1999
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The methods commonly used for human brucellosis serological testing are agglutination tests and the complement fixation test (CFT). Among the newer serological tests, primary binding assays were developed to improve sensitivity and specificity. The competitive enzyme immunoassay (CELISA) for the detection of serum antibody to Brucella is a multispecies assay which appears to be capable of differentiating vaccinal and cross-reacting antibodies from antibodies elicited by field infection in cattle. The competing monoclonal antibody used in this assay is specific for a common epitope of smooth lipopolysaccharide (S-LPS). In this study, we compared the CELISA to the classical tests for the diagnosis of human brucellosis. The CELISA cutoff value was determined to calculate its diagnostic specificity and sensitivity. A survey was performed with 911 sera. Of the sera, 341 were from an asymptomatic population that tested negative with conventional serological tests (screening and confirmatory). Based on these samples, the CELISA specificities were determined to be 99.7 and 100% with cutoff values of 28 and 30% inhibition (%I), respectively. In a further study with 393 additional sera from an asymptomatic population found negative by the conventional screening tests, the CELISA specificities were calculated to be 96.5 and 98.8% with cutoff values of 28 and 30%I. The CELISA sensitivities were determined to be 98.3 and 94.8% with cutoff values of 28 and 30%I, respectively, for sera from 116 individuals found positive by the classical tests. For the 51 culture-positive patients, CELISA was positive for 100%, the CFT was positive for 92%, and the standard tube agglutination test (TAT) was positive for 100%. The CELISA specificity was 100% for 31 sera from patients found negative by conventional serological tests but with brucellosis-like symptoms. The CELISA is fairly rapid to perform, somewhat faster than TAT, and cross-reacts less with other antigens (or antibodies) than the conventional tests. Further, the CELISA is simpler to perform that the CFT and may readily be standardized by the use of purified S-LPS antigen and monoclonal antibody for competition.
Fil: Lucero, Nidia E. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Foglia, Luis. Academia Nacional de Medicina de Buenos Aires. Centro de Investigaciones Epidemiológicas; Argentina.
Fil: Ayala, Sandra M. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Gall, David. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.
Fil: Nielsen, Klaus. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.
Fuente
Journal of Clinical Microbiology, 1999, 37(10), 3245–3248.
Materia
Brucelosis
Brucella
Anticuerpos Antibacterianos
Técnicas para Inmunoenzimas
Humanos
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:123456789/268

id SGCANLIS_8f05fcabc0c7cfb18b87f8abfdac99bf
oai_identifier_str oai:sgc.anlis.gob.ar:123456789/268
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Competitive enzyme immunoassay for diagnosis of human brucellosisLucero, Nidia E.Foglia, LuisAyala, Sandra M.Gall, DavidNielsen, KlausBrucelosisBrucellaAnticuerpos AntibacterianosTécnicas para InmunoenzimasHumanosThe methods commonly used for human brucellosis serological testing are agglutination tests and the complement fixation test (CFT). Among the newer serological tests, primary binding assays were developed to improve sensitivity and specificity. The competitive enzyme immunoassay (CELISA) for the detection of serum antibody to Brucella is a multispecies assay which appears to be capable of differentiating vaccinal and cross-reacting antibodies from antibodies elicited by field infection in cattle. The competing monoclonal antibody used in this assay is specific for a common epitope of smooth lipopolysaccharide (S-LPS). In this study, we compared the CELISA to the classical tests for the diagnosis of human brucellosis. The CELISA cutoff value was determined to calculate its diagnostic specificity and sensitivity. A survey was performed with 911 sera. Of the sera, 341 were from an asymptomatic population that tested negative with conventional serological tests (screening and confirmatory). Based on these samples, the CELISA specificities were determined to be 99.7 and 100% with cutoff values of 28 and 30% inhibition (%I), respectively. In a further study with 393 additional sera from an asymptomatic population found negative by the conventional screening tests, the CELISA specificities were calculated to be 96.5 and 98.8% with cutoff values of 28 and 30%I. The CELISA sensitivities were determined to be 98.3 and 94.8% with cutoff values of 28 and 30%I, respectively, for sera from 116 individuals found positive by the classical tests. For the 51 culture-positive patients, CELISA was positive for 100%, the CFT was positive for 92%, and the standard tube agglutination test (TAT) was positive for 100%. The CELISA specificity was 100% for 31 sera from patients found negative by conventional serological tests but with brucellosis-like symptoms. The CELISA is fairly rapid to perform, somewhat faster than TAT, and cross-reacts less with other antigens (or antibodies) than the conventional tests. Further, the CELISA is simpler to perform that the CFT and may readily be standardized by the use of purified S-LPS antigen and monoclonal antibody for competition.Fil: Lucero, Nidia E. ANLIS Dr.C.G.Malbrán; Argentina.Fil: Foglia, Luis. Academia Nacional de Medicina de Buenos Aires. Centro de Investigaciones Epidemiológicas; Argentina.Fil: Ayala, Sandra M. ANLIS Dr.C.G.Malbrán; Argentina.Fil: Gall, David. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.Fil: Nielsen, Klaus. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.1999info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1098-660Xhttp://sgc.anlis.gob.ar/handle/123456789/268http://jcm.asm.org/content/37/10/3245.full.pdf+htmlJournal of Clinical Microbiology, 1999, 37(10), 3245–3248.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISenginfo:eu-repo/semantics/openAccess2025-09-04T11:15:31Zoai:sgc.anlis.gob.ar:123456789/268Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:15:32.303Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Competitive enzyme immunoassay for diagnosis of human brucellosis
title Competitive enzyme immunoassay for diagnosis of human brucellosis
spellingShingle Competitive enzyme immunoassay for diagnosis of human brucellosis
Lucero, Nidia E.
Brucelosis
Brucella
Anticuerpos Antibacterianos
Técnicas para Inmunoenzimas
Humanos
title_short Competitive enzyme immunoassay for diagnosis of human brucellosis
title_full Competitive enzyme immunoassay for diagnosis of human brucellosis
title_fullStr Competitive enzyme immunoassay for diagnosis of human brucellosis
title_full_unstemmed Competitive enzyme immunoassay for diagnosis of human brucellosis
title_sort Competitive enzyme immunoassay for diagnosis of human brucellosis
dc.creator.none.fl_str_mv Lucero, Nidia E.
Foglia, Luis
Ayala, Sandra M.
Gall, David
Nielsen, Klaus
author Lucero, Nidia E.
author_facet Lucero, Nidia E.
Foglia, Luis
Ayala, Sandra M.
Gall, David
Nielsen, Klaus
author_role author
author2 Foglia, Luis
Ayala, Sandra M.
Gall, David
Nielsen, Klaus
author2_role author
author
author
author
dc.subject.none.fl_str_mv Brucelosis
Brucella
Anticuerpos Antibacterianos
Técnicas para Inmunoenzimas
Humanos
topic Brucelosis
Brucella
Anticuerpos Antibacterianos
Técnicas para Inmunoenzimas
Humanos
dc.description.none.fl_txt_mv The methods commonly used for human brucellosis serological testing are agglutination tests and the complement fixation test (CFT). Among the newer serological tests, primary binding assays were developed to improve sensitivity and specificity. The competitive enzyme immunoassay (CELISA) for the detection of serum antibody to Brucella is a multispecies assay which appears to be capable of differentiating vaccinal and cross-reacting antibodies from antibodies elicited by field infection in cattle. The competing monoclonal antibody used in this assay is specific for a common epitope of smooth lipopolysaccharide (S-LPS). In this study, we compared the CELISA to the classical tests for the diagnosis of human brucellosis. The CELISA cutoff value was determined to calculate its diagnostic specificity and sensitivity. A survey was performed with 911 sera. Of the sera, 341 were from an asymptomatic population that tested negative with conventional serological tests (screening and confirmatory). Based on these samples, the CELISA specificities were determined to be 99.7 and 100% with cutoff values of 28 and 30% inhibition (%I), respectively. In a further study with 393 additional sera from an asymptomatic population found negative by the conventional screening tests, the CELISA specificities were calculated to be 96.5 and 98.8% with cutoff values of 28 and 30%I. The CELISA sensitivities were determined to be 98.3 and 94.8% with cutoff values of 28 and 30%I, respectively, for sera from 116 individuals found positive by the classical tests. For the 51 culture-positive patients, CELISA was positive for 100%, the CFT was positive for 92%, and the standard tube agglutination test (TAT) was positive for 100%. The CELISA specificity was 100% for 31 sera from patients found negative by conventional serological tests but with brucellosis-like symptoms. The CELISA is fairly rapid to perform, somewhat faster than TAT, and cross-reacts less with other antigens (or antibodies) than the conventional tests. Further, the CELISA is simpler to perform that the CFT and may readily be standardized by the use of purified S-LPS antigen and monoclonal antibody for competition.
Fil: Lucero, Nidia E. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Foglia, Luis. Academia Nacional de Medicina de Buenos Aires. Centro de Investigaciones Epidemiológicas; Argentina.
Fil: Ayala, Sandra M. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Gall, David. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.
Fil: Nielsen, Klaus. Canadian Food Inspection Agency. Animal Diseases Research Institute; Canadá.
description The methods commonly used for human brucellosis serological testing are agglutination tests and the complement fixation test (CFT). Among the newer serological tests, primary binding assays were developed to improve sensitivity and specificity. The competitive enzyme immunoassay (CELISA) for the detection of serum antibody to Brucella is a multispecies assay which appears to be capable of differentiating vaccinal and cross-reacting antibodies from antibodies elicited by field infection in cattle. The competing monoclonal antibody used in this assay is specific for a common epitope of smooth lipopolysaccharide (S-LPS). In this study, we compared the CELISA to the classical tests for the diagnosis of human brucellosis. The CELISA cutoff value was determined to calculate its diagnostic specificity and sensitivity. A survey was performed with 911 sera. Of the sera, 341 were from an asymptomatic population that tested negative with conventional serological tests (screening and confirmatory). Based on these samples, the CELISA specificities were determined to be 99.7 and 100% with cutoff values of 28 and 30% inhibition (%I), respectively. In a further study with 393 additional sera from an asymptomatic population found negative by the conventional screening tests, the CELISA specificities were calculated to be 96.5 and 98.8% with cutoff values of 28 and 30%I. The CELISA sensitivities were determined to be 98.3 and 94.8% with cutoff values of 28 and 30%I, respectively, for sera from 116 individuals found positive by the classical tests. For the 51 culture-positive patients, CELISA was positive for 100%, the CFT was positive for 92%, and the standard tube agglutination test (TAT) was positive for 100%. The CELISA specificity was 100% for 31 sera from patients found negative by conventional serological tests but with brucellosis-like symptoms. The CELISA is fairly rapid to perform, somewhat faster than TAT, and cross-reacts less with other antigens (or antibodies) than the conventional tests. Further, the CELISA is simpler to perform that the CFT and may readily be standardized by the use of purified S-LPS antigen and monoclonal antibody for competition.
publishDate 1999
dc.date.none.fl_str_mv 1999
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 1098-660X
http://sgc.anlis.gob.ar/handle/123456789/268
http://jcm.asm.org/content/37/10/3245.full.pdf+html
identifier_str_mv 1098-660X
url http://sgc.anlis.gob.ar/handle/123456789/268
http://jcm.asm.org/content/37/10/3245.full.pdf+html
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Journal of Clinical Microbiology, 1999, 37(10), 3245–3248.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1842344418278899712
score 12.623145